TRVI
Trevi Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -4.3% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 3.53M | $50.51M | n/a | n/a |
| Q2 2026 | 73 | -1 | 67.22M | $1.24B | +7 | −8 |
| Q1 2026 | 77 | +2 | 59.43M | $710.63M | +8 | −6 |
| Q4 2025 | 75 | 0 | 58.45M | $731.74M | +1 | −1 |
| Q3 2025 | 18 | 0 | 44.17M | $404.20M | n/a | n/a |
| Q2 2025 | 15 | 0 | 25.58M | $139.93M | +1 | −1 |
| Q1 2025 | 12 | 0 | 12.85M | $80.81M | +1 | −1 |
| Q4 2024 | 12 | +4 | 15.26M | $62.88M | +4 | n/a |
| Q3 2024 | 7 | +3 | 5.91M | $19.73M | +3 | n/a |
| Q2 2024 | 4 | n/a | 5.62M | $16.74M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.21M | n/a | $44.88M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (passive) | 5.32M | n/a | $29.08M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | Marshall Wace ✦ | 2.48M | -3.0% | $13.55M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 1.83M | +28.7% | $10.03M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.79M | +10.7% | $9.78M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 1.73M | -27.0% | $9.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Viking Global Investors ✦ | 1.54M | -52.2% | $8.44M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.32M | New | $7.22M | 0.0% | New | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 489.30K | +450.4% | $2.68M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 368.53K | n/a | $2.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Wellington Management ✦ | 171.98K | +34.9% | $940,742 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 157.24K | -80.9% | $860,125 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 120.24K | +2.1% | $657,713 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 38.55K | +19.9% | $211,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 24.83K | -10.4% | $135,821 | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $7.22M | 0.0% |
Exited
| Adage Capital Partners | $2.77M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 198 holders, 134.86M shares, $1.61B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 18.32K sh · $276,464
Director · 100 sh · $1,588
Director · 20.95K sh · $316,166
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology